![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
April 27, 2021
In this interview, Dr. Peter O'Dwyer urges physicians, sites, and testing laboratories to redouble efforts to locate patients for 12 open arms
March 31, 2021
This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
March 31, 2021
This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
March 31, 2021
The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
January 25, 2021
This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
January 25, 2021
This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma